Accessing Fintepla

Talk to us to find out how to access Fintepla in your country

If you are based in Estonia, Finland, Hungary, Iceland, Ireland, Liechtenstein, Luxembourg, Poland, Slovenia or Sweden, and you would like to learn more, or have a discussion about Fintepla (fenfluramine) and its indication for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older,1 our Key Account Manager (KAM) Olivia will be able to help.


Alternatively, if you have a Medical Information query please contact Medical Information on +44 (0) 800 060 8767 or email medinfo.eu@zogenix.com

Olivia

Olivia Guzicki

Digital Key Account Manager Europe

oguzicki@zogenix.com

+44 (0) 1530 686 148

+44 (0) 759 989 21 81

Hello, my name is Olivia and I am your Zogenix Account Manager. 


My origin is Polish, but I was born and grew up in Berlin, Germany. 

I am proud to work for Zogenix International Limited in your country, as a Digital Key Account Manager introducing Fintepla. 


Why am I doing this role? The answer is very easy, I get a huge amount of satisfaction from knowing that I could play a part in potentially improving a patient’s life. I speak a number of languages and am very much looking forward to talking with you soon. 

If you are a healthcare professional practising in a country not listed above and you have a medical enquiry, then please contact Medical Information on +44 (0) 800 060 8767 or email medinfo.eu@zogenix.com

View references

  1. Fintepla Summary of Product Characteristics.

Adverse events should be reported.

Please refer to section 4.8 of the SmPC for national reporting requirements in your country.

Adverse events should also be reported to Zogenix International Limited on +44 (0)800 060 8767 or email medinfo.eu@zogenix.com